Should I invest in ITI Pharma and Healthcare Fund?

We don't give personal investment advice. ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is suitable for an investor whose:time horizon is **5+ years** — equity funds can drop 30-50% in bad years; horizons under 5 years materially raise the risk of selling at a lossrisk tolerance accepts seeing the portfolio fall sharply without panic-sellinggoal isn't capital preservation in the short termCross-check the numbers above against alternatives before deciding.

ITI

ITI Pharma and Healthcare Fund - Direct Plan - Growth Option

Latest NAV

₹19.1660

As of

17 Jul 2026

1,152 NAV records on file

NAV history & peer comparison

All NAVs split-adjusted and normalised to 100 at the start of the selected period, so funds with very different absolute NAV scales can be compared on one axis.

Period

Add another fund to compare

No matches.

Compares up to 8 funds. Click any line in the legend above to hide/show it.

Returns matrix

Fund return alongside the category average and peer rank for every standard window. Returns under one year are absolute; one year and longer are compound annualised (CAGR).

Window	Fund	Category avg	+/− vs avg	Rank	Quartile
1D	-1.18%	-0.05%	-1.13	245 / 258	Q4
1W	-0.51%	-0.18%	-0.32	186 / 258	Q3
2W	-0.88%	-0.17%	-0.71	221 / 259	Q4
1M	+5.48%	+1.63%	+3.85	23 / 259	Q1
3M	+13.07%	+4.83%	+8.24	24 / 259	Q1
6M	+14.90%	+4.61%	+10.29	30 / 250	Q1
YTD	+12.67%	+2.98%	+9.69	26 / 247	Q1
1Y	+5.56%	+5.46%	+0.11	106 / 235	Q2
2Y	+10.67%	+4.09%	+6.58	29 / 187	Q1
3Y	+20.93%	+15.93%	+5.00	32 / 148	Q1
4Y	+20.00%	+17.58%	+2.41	45 / 121	Q2
5Y	—	—	—	—	—
7Y	—	—	—	—	—
10Y	—	—	—	—	—
Inception	+14.89%	+12.07%	+2.82	106 / 259	Q2

Quartile legend: Q1 top 25% Q2 25-50% Q3 50-75% Q4 bottom 25%

Calendar-year returns

Full-year performance vs category average. Current year is partial (year-to-date).

Year	Fund	Category avg	+/− vs avg	Rank
2026 YTD	+12.67%	+3.40%	+9.27	26 / 244
2025	-8.79%	+4.41%	-13.20	201 / 208
2024	+43.59%	+23.18%	+20.41	5 / 155
2023	+35.22%	+33.51%	+1.70	52 / 127
2022	-6.68%	+4.32%	-11.01	93 / 116
2021	—	—	—	—

Rolling returns

Removes start-date bias by averaging CAGR over every overlapping N-year window in the fund's history. Higher average plus tight min/max plus high "% positive" = consistent.

1-Year rolling

+19.95%

45 windows

min -6.7% · max 59.9%

87% positive

Limited basis — fund is young, so this average may be skewed by which 1Y windows happen to be available.

3-Year rolling

+22.30%

21 windows

min 19.6% · max 25.5%

100% positive

Limited basis — fund is young, so this average may be skewed by which 3Y windows happen to be available.

5-Year rolling

—

Insufficient history

7-Year rolling

—

Insufficient history

SIP returns — historical "what if"

If you had invested every month in this fund over the chosen period, this is what your investment would be worth today.

Period

Total invested

₹ —

Today's value

₹ —

XIRR

Annualised

Wealth multiplier

Period	Total invested	Today's value	XIRR	Wealth multiplier

XIRR is the annualised internal rate of return on the SIP cash flow — invariant to the monthly amount. "Today's value" and "Total invested" scale linearly with the slider. Past performance does not guarantee future returns. Excludes exit load and taxes.

Risk profile

Risk-adjusted return and volatility, computed from monthly NAV returns over the trailing 3-year and 5-year windows.

Std deviation

13.33%

3-year · annualised

Sharpe ratio

1.00

vs risk-free 6.5%

Sortino ratio

2.12

Downside-only deviation

Max drawdown

-17.07%

Jan 2025 → Mar 2025

% positive months

61.1%

Share of monthly returns > 0 over the 3-year window

Sharpe / Sortino use a risk-free rate of 6.5% (1-year T-bill proxy). Higher Sharpe = more return per unit of total risk; higher Sortino = more return per unit of downside risk.

Peers in Sectoral/Thematic Fund

Scheme	Fund house	NAV	As of
HDFC Banking & Financial Services Fund - Growth Option - Direct Plan	HDFC	₹19.7420	17 Jul 2026
Nippon India Active Momentum Fund-Direct Plan - Growth Option	Nippon India	₹13.0154	17 Jul 2026
SBI Automotive Opportunities Fund - Direct Plan - Growth	SBI	₹12.5868	17 Jul 2026
ICICI Prudential Active Momentum Fund - Direct Plan - Growth	ICICI Prudential	₹10.8700	17 Jul 2026
Invesco India Business Cycle Fund - Direct Plan - Growth	Invesco	₹14.5000	17 Jul 2026
Bandhan Business Cycle Fund - Direct Plan - Growth	Bandhan	₹10.1960	17 Jul 2026
quant BFSI Fund - Growth Option - Direct Plan	Quant	₹22.0723	17 Jul 2026
QUANTUM ESG BEST IN CLASS STRATEGY FUND - DIRECT PLAN - GROWTH OPTION	Quantum	₹24.7900	17 Jul 2026
Aditya Birla Sun Life Banking and Financial Services Fund - Direct Plan - Growth	Aditya Birla Sun Life	₹72.8200	17 Jul 2026
Motilal Oswal Active Momentum Fund- Direct-Growth	Motilal Oswal	₹13.5242	17 Jul 2026

Recent NAVs

Date	NAV
17 Jul 2026	₹19.1660
16 Jul 2026	₹19.3939
15 Jul 2026	₹19.3917
14 Jul 2026	₹19.3220
13 Jul 2026	₹19.2137
10 Jul 2026	₹19.2636
9 Jul 2026	₹19.2077
8 Jul 2026	₹18.9548
7 Jul 2026	₹19.1883
6 Jul 2026	₹19.3474

Frequently asked questions

These answers are generated from this fund's live metrics — NAV, returns, peer rank, drawdown, SIP backtest. Numbers refresh nightly after AMFI's NAV feed lands.

As of 17 Jul 2026, the NAV of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is ₹19.1660. It's a Sectoral/Thematic Fund from ITI, run as a Direct plan Growth option. NAVs update once per business day from the AMFI feed.

ITI Pharma and Healthcare Fund - Direct Plan - Growth Option has NAV history starting from 11 Nov 2021, a track record of about 4 years 8 months. It's a relatively new scheme. With under 5 years of NAVs, peer comparison is the best yardstick — point-to-point returns can be skewed by entry timing.

ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is managed by ITI. It's classified by AMFI under the 'Sectoral/Thematic Fund' SEBI category, which determines its peer set and tax treatment.

Over the trailing 1-year window, ITI Pharma and Healthcare Fund - Direct Plan - Growth Option has delivered a absolute return of 5.56% — +0.11 pp ahead of the Sectoral/Thematic Fund category average of 5.46%. The fund ranks #106 of 235 in its category — the second (Q2) quartile.

Over the trailing 3-year window, ITI Pharma and Healthcare Fund - Direct Plan - Growth Option has delivered a CAGR of 20.93% — +5 pp ahead of the Sectoral/Thematic Fund category average of 15.93%. The fund ranks #32 of 148 in its category — the top (Q1) quartile.

ITI Pharma and Healthcare Fund - Direct Plan - Growth Option doesn't have a complete 5-year window yet (we need at least 5 year of NAVs). Check the shorter-window returns above.

₹1 lakh invested in ITI Pharma and Healthcare Fund - Direct Plan - Growth Option exactly 3 years ago would be worth approximately ₹176,857 today — a multiplier of 1.77×, based on the 3-year CAGR of 20.93%. The category average over the same window would have grown ₹1 lakh to ₹155,796.

A ₹10,000 monthly SIP in ITI Pharma and Healthcare Fund - Direct Plan - Growth Option over the last 3 years — total invested ₹360,000 — would be worth ₹447,289 today. That's an XIRR (money-weighted annualised return) of 14.62%.

ITI Pharma and Healthcare Fund - Direct Plan - Growth Option doesn't yet have 10 years of NAVs. Over the longest available window (3-year SIP), ₹10,000/month would have grown to ₹447,289 — XIRR 14.62%.

On a 3-year basis, ITI Pharma and Healthcare Fund - Direct Plan - Growth Option ranks #32 out of 148 funds in the Sectoral/Thematic Fund category — that places it in the top quartile (Q1) — strong outperformance. The category average return over the same window is 15.93%; this fund delivered 20.93%.

The worst peak-to-trough decline ITI Pharma and Healthcare Fund - Direct Plan - Growth Option has experienced over the last 3-year window is 17.07% — its NAV fell from a high on 02 Jan 2025 to a low on 03 Mar 2025. Drawdown is a useful gauge of how much short-term pain you'd have endured to capture the long-term return.

Across all 3-year rolling windows, ITI Pharma and Healthcare Fund - Direct Plan - Growth Option averaged 22.30% (best 25.46%, worst 19.58%). 100% of rolling windows ended positive. The 3-year Sharpe ratio is 1.00 — reasonable risk-adjusted performance.

In calendar year 2025, ITI Pharma and Healthcare Fund - Direct Plan - Growth Option returned -8.79% — lagging the Sectoral/Thematic Fund category average of 4.41% by 13.20 pp. It ranked #201 of 208 in its category that year.

ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is classified as an Equity fund (at least 65% equity exposure). Tax rules (post Budget 2024): if you hold 12 months or more, gains are Long-Term and taxed at 12.5% on the amount exceeding ₹1.25 lakh per financial year. Held for under 12 months, gains are Short-Term and taxed at 20%. The ₹1.25 L exemption is per PAN per FY across all equity LTCG.

We don't give personal investment advice. ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is suitable for an investor whose:

time horizon is **5+ years** — equity funds can drop 30-50% in bad years; horizons under 5 years materially raise the risk of selling at a loss
risk tolerance accepts seeing the portfolio fall sharply without panic-selling
goal isn't capital preservation in the short term

Cross-check the numbers above against alternatives before deciding.

Educational content only — not investment advice. Tax rules summarised above reflect Budget 2024; consult a qualified adviser before transacting.